HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Multinationals Turn To Smaller Markets To Avoid BRIC Restrictions

This article was originally published in PharmAsia News

Executive Summary

Poland, Mexico, South Korea and Indonesia all grew between 5% and 6.5% in 2011, and South Africa, Turkey, Vietnam, the “stans” countries and “fascinatingly” Iran, among others, also are likely areas for future expansion of the OTC and self-care market, consultant Nicholas Hall says.

You may also be interested in...

Genomma Targets Prestige’s Objections To Takeover

Genomma Lab shareholders approve an unsolicited bid for Prestige Brands with permission to up the ante. In another development that comes as Prestige closes the acquisition of 17 OTC brands from GSK, Prestige acknowledges Genomma’s slate of board nominees to be voted on at a June 29 shareholder meeting.

Squeezed by Price Caps And Rising Costs, China's Nepstar Drugstore Chain Pushes Its Own Brands

Want to get beverages on a drug store run for aspirin in China? Not a problem in Nepstar stores, where China's largest retail pharmacy chain is increasingly becoming more of a convenience store than a traditional drug store. It is shifting its business model to focus on private label products to fend off a double squeeze: swelling rental and labor costs and ongoing governmental reform initiatives to impose price caps on drug retailers

Russia’s Emerging OTC Market Holds Problems As Well As Promise

Russia's rapidly growing over-the-counter market offers pharmaceutical companies a chance to expand their business, but its complex regulations and lengthy registration timelines may hinder entry


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts